Epstein-Barr virus latency antigens

Epstein-Barr virus (EBV) latency antigens, primarily including EBNA1, LMP1, and LMP2, are viral proteins expressed during the latent phase of EBV infection and are characteristic of EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin's lymphoma. These antigens are critical for maintaining the viral genome and driving cell transformation, making them ideal targets for immunotherapy. In therapeutic contexts, these antigens are loaded onto autologous dendritic cells to be presented via MHC class I and II molecules, effectively priming and expanding EBV-specific CD4+ and CD8+ T lymphocytes. This approach, often delivered as a personalized dendritic cell vaccine, leverages the host's immune system to recognize and eliminate tumor cells expressing these specific viral proteins. Clinical trials have demonstrated that this strategy can induce robust immune responses and provide clinical benefits in patients with recurrent or metastatic EBV-positive cancers. The efficacy of such treatments is typically monitored through biomarkers like EBV DNA load and T-cell response assays.

Other names

Epstein-Barr virus latent antigensEBV latent proteinsEBNA1LMP1LMP2EBV-associated tumor antigens

Induction of antigen-specific CD4+ and CD8+ T cell responses through presentation on MHC molecules of autologous dendritic cells, leading to the destruction of EBV-infected tumor cells.